Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Erlotinib attacks a part of cancer cells that helps them live and grow. Studies done in human
beings show that this drug can make a difference in the way anti-estrogens work in
hormone-sensitive breast cancers. OSI-906 attacks a different part of the cancer cell that
helps them live and grow. Studies done in the laboratory show that OSI-906 can make a
difference in the way anti-estrogens work in hormone-sensitive breast cancers.